Laurus Labs: Brokerages Bullish as CDMO Shift Drives Growth

Laurus Labs has witnessed a stellar 30% rally in its share price over the last two months, fueled by a strategic pivot toward high-value segments. As the company transitions from traditional therapies to specialized manufacturing, analysts are raising earnings estimates to reflect a robust growth trajectory.

Strategic Pivot: The Rise of CDMO and Reduced ARV Reliance

A central driver of Laurus Labs' recent performance is its structural transformation. The company is successfully shifting its focus from traditional antiretroviral (ARV) therapies to the high-growth Contract Development and Manufacturing Organisation (CDMO) segment. Six years ago, CDMO contributed just 13% to total revenue; in FY26, this figure surged to over 30%. Management expects this segment to command 50% of total revenue by FY30.

Parallel to this growth, the company has significantly de-risked its portfolio by reducing dependence on ARV therapies. The contribution of ARVs to the revenue mix has declined from 67% to approximately 41%, allowing the company to tap into more lucrative and diversified pharmaceutical markets.

Explosive CDMO Growth and Margin Expansion

The CDMO segment recorded a massive 36% year-on-year growth in FY26, reaching ₹2,080 crore. This momentum is underpinned by progress in late-stage pipelines, the commercialization of novel molecules, and increased outsourcing demands from global pharmaceutical giants. Motilal Oswal Financial Services (MOFSL) projects the segment will maintain a 22% annual growth rate through FY26-28.

This volume growth, coupled with improved operating leverage, has significantly bolstered profitability. The EBITDA margin expanded by an impressive 670 basis points year-on-year to reach 26.8%. While future margins will depend on raw material price stability, the current trajectory remains highly positive.

Aggressive ₹3,000-Crore Capex Plan

To sustain this momentum, Laurus Labs has announced a massive capital expenditure plan of ₹3,000 crore over the next two years. More than 90% of this capital is earmarked for expanding mid and large-scale manufacturing capacities. Key initiatives include:

  • Greenfield Expansion: The development of the Unit 7 facility, featuring over 2,000 cubic meters of reactor capacity.
  • Capacity Validation: A second commercial block is slated for validation by the September 2026 quarter.
  • Diversification: Significant investments in peptides, fermentation, advanced therapies, and animal health.

Furthermore, the company is eyeing non-pharma segments like crop science. From a current base of ₹150 crore, MOFSL anticipates these segments could eventually scale beyond ₹1,000 crore.

Analyst Outlook and Earnings Projections

Reflecting confidence in these developments, brokerages like MOFSL have maintained a 'BUY' rating. Analysts have revised earnings estimates upward, increasing projections for FY27 by 8% and for FY28 by 6%. This optimism is rooted in the company's ability to balance steady growth in existing segments with aggressive expansion in high-margin, specialized manufacturing.

Key Takeaways

  • Structural Shift: CDMO revenue has jumped from 13% to over 30% in six years, with a target of 50% by FY30.
  • Margin Strength: Operating EBITDA margins expanded by 670 basis points YoY to reach 26.8%.
  • Future Investment: A ₹3,000-crore capex plan is underway to expand manufacturing in CDMO, peptides, and animal health.